Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nigrostriatal dysfunction in homozygous and heterozygous <i>parkin</i> gene carriers: An <sup>18</sup>F‐dopa PET progression study

20 Oct 2009

Abstract excerpt

Little is known about the rate of progression of striatal dysfunction in subjects with parkin-linked parkinsonism. Being a heterozygous parkin gene carrier may confer susceptibility to Parkinson's disease (PD). In a previous (18)F-dopa PET study, we reported that 69% of carriers of a single parkin mutation showed subclinical loss of putamen dopaminergic function. Using serial (18)F-dopa PET, the present...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurological disorders and treatments
Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19845000
DOI: 10.1002/mds.22817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nigrostriatal dysfunction in homozygous and heterozygous <i>parkin</i> gene carriers: An <sup>18</sup>F‐dopa PET progression studyPMID 19845000Read ↗

Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical studySemantic proximity Read ↗

Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation.Semantic proximity Read ↗

Dopaminergic function in familial Parkinson's disease: A clinical and <sup>18</sup>F‐dopa positron emission tomography studySemantic proximity Read ↗

PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.Semantic proximity Read ↗

Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit.Semantic proximity Read ↗

Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography.Semantic proximity Read ↗

A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations.Semantic proximity Read ↗

[18 F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations.Semantic proximity Read ↗

Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers.Semantic proximity Read ↗

Serial DaT-SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years' follow-up.Semantic proximity Read ↗

Asymptomatic carriers of the p.A53T SNCA mutation: data from the PPMI studySemantic proximity Read ↗

In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.